{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T09:24:47Z","timestamp":1788341087435,"version":"build-2803163510"},"reference-count":26,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objectives: Male breast cancer (MBC) is a rare malignancy accounting for less than 1% of all breast cancers, and current treatment recommendations are largely extrapolated from studies in women. We aimed to evaluate the clinicopathological characteristics, treatment patterns, survival outcomes, and prognostic factors of male breast cancer patients treated at a tertiary referral center. Methods: We retrospectively reviewed 45 patients with histopathologically confirmed MBC treated between January 2015 and July 2025. Demographic, clinicopathological, treatment, and follow-up data were collected from institutional records. Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan\u2013Meier method, and potential prognostic factors were analyzed using univariate Cox proportional hazards regression. Results: The median age at diagnosis was 60 years, and invasive ductal carcinoma was the predominant histological subtype (95.6%). Estrogen and progesterone receptor positivity were observed in 93.0% and 95.2% of patients, respectively, while HER2 positivity was identified in 26.8%. Modified radical mastectomy was performed in 95.6% of patients, adjuvant endocrine therapy in 88.9%, chemotherapy in 73.3%, and radiotherapy in 64.4%. After a median follow-up of 84 months (range, 1\u2013125 months), the estimated 5-year OS and DFS rates were 85.3% and 68.4%, respectively. No locoregional recurrence was observed in the entire cohort; all recurrences were distant metastases. None of the evaluated clinicopathological variables demonstrated a statistically significant association with OS or DFS. Conclusions: This single-center experience demonstrates favorable long-term survival and no observed locoregional recurrence in a contemporary cohort of patients with male breast cancer. These real-world findings are consistent with current treatment strategies and provide additional evidence regarding the management of this rare disease. Larger multicenter collaborative studies are needed to establish robust prognostic models and generate male-specific evidence to further optimize clinical management.<\/jats:p>","DOI":"10.3390\/jcm15176800","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:56:01Z","timestamp":1788339361000},"page":"6800","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Male Breast Cancer: An Analysis of Clinicopathological Features, Treatment Patterns, and Survival Outcomes over 10 Years from a Tertiary Center"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6571-4114","authenticated-orcid":false,"given":"H\u00fcseyin","family":"Tepetam","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul 34865, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6095-3506","authenticated-orcid":false,"given":"Cemal Ugur","family":"Dursun","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul 34865, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1006-7049","authenticated-orcid":false,"given":"Mustafa Mert","family":"Hanilce","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul 34865, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Solen","family":"Nasifoglu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul 34865, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9972-5872","authenticated-orcid":false,"given":"Nursena","family":"Ciflik","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul 34865, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Duygu","family":"Gedik","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul 34865, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Sermin","family":"Kokten","sequence":"additional","affiliation":[{"name":"Department of Medical Pathology, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul 34865, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"resources","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4219-8900","authenticated-orcid":false,"given":"Sule","family":"Karabulut Gul","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul 34865, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.seminoncol.2017.11.002","article-title":"Male Breast Cancer: Epidemiology and Risk Factors","volume":"44","author":"Yousef","year":"2017","journal-title":"Semin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1038\/s41598-025-85954-8","article-title":"Long-term trends in the incidence of male breast cancer and nomogram for predicting survival in male breast cancer patients: A population-based epidemiologic study","volume":"15","author":"Huang","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s12672-025-02140-y","article-title":"Decoding male breast cancer: Epidemiological insights, cutting-edge treatments, and future perspectives","volume":"16","author":"Zhao","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.32604\/or.2025.068238","article-title":"Male Breast Cancer: Epidemiology, Diagnosis, Molecular Mechanisms, Therapeutics, and Future Prospective","volume":"34","author":"Sah","year":"2026","journal-title":"Oncol. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10549-018-4921-9","article-title":"Male breast cancer: A disease distinct from female breast cancer","volume":"173","author":"Gucalp","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/cncr.32472","article-title":"Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century","volume":"126","author":"Yadav","year":"2020","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"10732748251335365","DOI":"10.1177\/10732748251335365","article-title":"Characteristics, Treatment, and Survival of Male Breast Cancer: A 21-year Retrospective Analysis at a Community Academic Institute in Central Illinois","volume":"32","author":"Azhar","year":"2025","journal-title":"Cancer Control"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Forster, T., K\u00f6hler, C., El Shafie, R., Weykamp, F., K\u00f6nig, L., Arians, N., Adeberg, S., Michel, L., Smetanay, K., and Golatta, M. (2020). Adjuvant Radiation Therapy for Male Breast Cancer\u2014A Rare Indication?. Cancers, 12.","DOI":"10.3390\/cancers12123645"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1111\/1759-7714.13611","article-title":"Male breast cancer: A closer look at patient and tumor characteristics and factors associated with survival","volume":"11","author":"Zhao","year":"2020","journal-title":"Thorac. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1159\/000335204","article-title":"Clinicopathological Characteristics and Survival Analysis of 87 Male Breast Cancer Cases","volume":"6","author":"Liu","year":"2011","journal-title":"Breast Care"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Gargiulo, P., Pensabene, M., Milano, M., Arpino, G., Giuliano, M., Forestieri, V., Condello, C., Lauria, R., and De Placido, S. (2016). Long-term survival and BRCA status in male breast cancer: A retrospective single-center analysis. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2414-y"},{"key":"ref_12","unstructured":"Amin, M.B., Edge, S.B., Greene, F.L., Byrd, D.R., Brookland, R.K., Washington, M.K., Gershenwald, J.E., Compton, C.C., Hess, K.R., and Sullivan, D.C. (2017). AJCC Cancer Staging Manual, Springer. [8th ed.]."},{"key":"ref_13","unstructured":"White, J., Tai, A., Arthur, D., Buchholz, T., MacDonald, S., Marks, L., Pierce, L., Recht, A., Rabinovitch, R., and Taghian, A. (2026, May 15). Breast Cancer Atlas for Radiation Therapy Planning: Consensus Definitions. Radiation Therapy Oncology Group (RTOG). Available online: https:\/\/www.nrgoncology.org\/wp-content\/uploads\/2026\/01\/BreastCancerAtlas_corr.pdf."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1038\/s41598-025-86556-0","article-title":"HER2 expression and pathway status in male breast cancer patients: Results of an integrated analysis among 6,150 patients","volume":"15","author":"Lyu","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Silvestri, V., Valentini, V., Bucalo, A., Conti, G., Manzella, L., Turchetti, D., Russo, A., Capalbo, C., and Ottini, L. (2024). HER2-Low Expression in Male Breast Cancer: Results from a Multicenter Series in Italy. Cancers, 16.","DOI":"10.3390\/cancers16030548"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/jamaoncol.2019.2803","article-title":"Overall Mortality After Diagnosis of Breast Cancer in Men vs Women","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/annonc\/mdx651","article-title":"Characterization of male breast cancer: Results of the EORTC 10085\/TBCRC\/BIG\/NABCG International Male Breast Cancer Program","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.ijrobp.2011.01.010","article-title":"The Impact of Post-Mastectomy Radiation Therapy on Male Breast Cancer Patients\u2014A Case Series","volume":"82","author":"Yu","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000354122","article-title":"Male Breast Cancer: 20-Year Survival Data for Post-Mastectomy Radiotherapy","volume":"8","author":"Eggemann","year":"2013","journal-title":"Breast Care"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1200\/JCO.19.03120","article-title":"Management of Male Breast Cancer: ASCO Guideline","volume":"38","author":"Hassett","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10549-012-2355-3","article-title":"Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients","volume":"137","author":"Eggemann","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/jamaoncol.2020.7442","article-title":"Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men: Results from the MALE Phase 2 Randomized Clinical Trial","volume":"7","author":"Reinisch","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/cncr.33899","article-title":"Adjuvant tamoxifen adherence in men with early-stage breast cancer","volume":"128","author":"Oke","year":"2022","journal-title":"Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/bjs\/znab279","article-title":"Treatment of male breast cancer: Meta-analysis of real-world evidence","volume":"108","author":"Lin","year":"2021","journal-title":"Br. J. Surg."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e990","DOI":"10.1634\/theoncologist.2019-0871","article-title":"Exclusion of Men from Randomized Phase III Breast Cancer Clinical Trials","volume":"25","author":"Corrigan","year":"2020","journal-title":"The Oncologist"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10555-018-9761-x","article-title":"A contemporary review of male breast cancer: Current evidence and unanswered questions","volume":"37","author":"Giridhar","year":"2018","journal-title":"Cancer Metastasis Rev."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6800\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T09:11:55Z","timestamp":1788340315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":26,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15176800"],"URL":"https:\/\/doi.org\/10.3390\/jcm15176800","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]}}}